24.06.20 ijBio Portfolio

Pharm Involved.

$1,000,000 on 12.06.20 Changes for 24.06.20:

AstraZeneca (AZN) $51,3 $52,1 (+1.6%) $101,600

Inovio (INO) $13,2 $23,9 (+81%) $181,000

Moderna (MRNA)$61,5 $64,8 (+5.3%) $105,300

Abbot (ABT) $88,5 $87,3 (+1.6%) $98,400

Gilead (GILD) $72,5 $75,9 (+4.7%) $104,700

Adaptive (ADPT) $42,2 $45,8 (+8.5%) $108,500

CytoDyn (CYDY) $3,12 $5 (+60.2%) $160,200

AbbVie (ABBV) $92,2 $95,1 (+3.3%) $103,300

Arcus (RCUS) $27,3 $24,2 (-11.3%) $88,700

Sorrento (SRNE) $4,6 $5,56 (+20,9%) $120,900

At close 24.06.20= $1,172,600 (+3%)

per million dollars at 10% per share.

previous day

At close 23.06.20= $ 1,137,900 (+5,2%)

At close 22.06.20= $1,081,600 ( +4,8%)

At close 19.06.20= $1,057,500

during the week 12-19.06 +3%

12.06.20 = $1,000,000

Global Communication Platforms portfoilio

--

Portfolio News:

US Indexes Close Lower Wednesday With Coronavirus Concerns

Sosei, AbbVie sign drug discovery deal worth up to $1 billion

Unilever, rivals mull changes amid global backlash against skin-lightening products

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of SRNE, WFC and ENDP

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sorrento Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SRNE

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sorrento Therapeutics, Carnival Corporation, Wells Fargo, and Hebron Technology and Encourages Investors to Contact the Firm

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that is Not Curable by Surgery or Radiation

Abbott Labs Cuts Ties With GOP Lobbyist Matt Schlapp

Top Research Reports for Amazon, Alibaba & NIKE

PT010 Significantly Reduced Rate of Moderate or Severe COPD Exacerbations in Phase III ETHOS Trial

Here are the factors, and the stocks, that will help you play the COVID-19 market

South Africa rolls out continent's first trials for COVID-19 vaccine

U.S. group raises pricing recommendation for Gilead's remdesivir in COVID-19

A Trio of Strong Performers to Consider

CLASS ACTION UPDATE for SRNE, CEMI and CSPR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Gilead to Buy 49.9% Stake in Private Biotech for $275M

Sanofi (SNY) is a Top Dividend Stock Right Now: Should You Buy?

Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?

Inovio Pharmaceuticals Gets $71M for Vaccine-Delivery Device

FuelCell Energy: Rising From the Brink of Bankruptcy

Appeals Court Rules Against J&J but Cuts Talc- Powder Verdict

• Yahoo Finance

Advertise With Us

© 2020 Verizon Media. All rights reserved.

Data DisclaimerHelpSuggestions

Privacy (Updated)About Our AdsTerms (Updated)Sitemap

• Infojet Club